A novel C-terminal domain Hsp90 inhibitor, SL-145, effectively suppressed metastatic triple-negative breast cancers by inhibiting oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling, and without an induction of the heat shock response [106]. The gene discussed is HSP90AA1; the disease is triple-negative breast carcinoma.